Novel Targets in the Ovarian Cancer Treatment Paradigm
The Novel Targets in the Ovarian Cancer Treatment Paradigm publication covers some of the latest practice-changing advances as it relates to novel targets in the treatment for patients with advanced ovarian cancer.
Volume: 1
Issue: 1
MK-1084 Alone and Plus Pembrolizumab Shows Early Safety, Activity in KRAS G12C+ Solid Tumors
First-Line Anlotinib Plus Etoposide and Carboplatin Improves PFS in ES-SCLC
Concurrent Durvalumab/CRT Does Not Confer Significant Survival Advantage in Unresectable Stage III NSCLC
Phase 2 IMscin002 Study Shows Patients With NSCLC Prefer Subcutaneous Atezolizumab